Key result
Cilnidipine significantly reduced serum triglyceride levels from 172.46 mg/dL at baseline to 162.46 mg/dL after 12 weeks of treatment in patients with essential hypertension and borderline dyslipidemia.
Why the study?
Does cilnidipine improve blood pressure and lipid profiles in patients with essential hypertension and borderline dyslipidemia?
RCT (n=37)
Open-label
Randomized
No
Does cilnidipine improve blood pressure and lipid profiles in patients with essential hypertension and borderline dyslipidemia?
Cilnidipine effectively lowers both blood pressure and serum triglycerides in patients with essential hypertension and borderline dyslipidemia.
BACKGROUND: Many epidemiological studies have established the relationship between hypertension and dyslipidemia. Calcium channel blockers (CCBs) are one of the first-line drugs for newly diagnosed patients with essential hypertension. Cilnidipine as a newer CCB acting by blocking both L- and N-type calcium channels possesses additional beneficial effects apart from lowering blood pressure (BP). The aim of this study was to evaluate the effectiveness of cilnidipine in patients with essential hypertension with borderline dyslipidemia and its effects on lipid profile. METHODS: Out of 45 enrolled patients, who fulfilled the inclusion criteria, only 37 completed the study. Cilnidipine was started at 10 mg/day, and then adjusted to 5 - 20 mg/day to achieve the target blood pressure. RESULTS: After 12 weeks of study, patients showed significant reduction in systolic blood pressure, diastolic blood pressure, mean BP, heart rate and serum triglyceride level from baseline values (P < 0.00). CONCLUSION: In clinical setting where both hypertension and hypertriglyceridemia exist, cilnidipine can be a promising drug of choice.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2016) conducted an RCT in Essential hypertension with borderline dyslipidemia (n=37). Cilnidipine vs. Baseline was evaluated on Serum triglyceride level (mg/dL) (p=<0.01). Cilnidipine significantly reduced serum triglyceride levels from 172.46 mg/dL at baseline to 162.46 mg/dL after 12 weeks of treatment in patients with essential hypertension and borderline dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: